Acyclovir is NOT contraindicated in viral hepatitis in infants
Acyclovir can be safely used in infants with viral hepatitis, particularly when herpes simplex virus (HSV) is the suspected or confirmed etiology. The available evidence demonstrates that acyclovir is not only safe but potentially life-saving in this population when HSV hepatitis is present.
Key Evidence Supporting Safety and Use
FDA-Approved Indications and Safety Profile
The FDA drug label for acyclovir 1 does not list viral hepatitis as a contraindication. The only absolute contraindication is hypersensitivity to acyclovir or valacyclovir 1. While rare adverse events include hepatitis, this is an uncommon side effect rather than a contraindication for use in patients with existing hepatitis.
Neonatal HSV Disease Guidelines
For neonatal HSV infections (which can present as hepatitis), acyclovir 20 mg/kg IV three times daily is the standard of care 2. The treatment duration is:
- 14 days for skin, eye, or mouth disease
- 21 days for CNS or disseminated disease (which includes hepatitis)
Safety Data in Infants
A comprehensive safety study of 89 infants treated with high-dose acyclovir (60 mg/kg/day) for neonatal HSV disease found 3:
- Adverse events were common (45% of infants) but usually not severe
- Most adverse events were likely related to the underlying infection rather than acyclovir
- Elevated creatinine occurred in only 2% of infants
- No infants developed renal failure requiring dialysis
- Thrombocytopenia was the most common laboratory finding (25% of infants)
Clinical Evidence for HSV Hepatitis
Early empirical acyclovir treatment is life-saving in HSV hepatitis 4. A case series demonstrated that:
- HSV hepatitis presents with fever, elevated transaminases, and mucositis without clear cutaneous lesions
- Delayed diagnosis is common and contributes to high mortality
- Early empirical acyclovir therapy before diagnostic confirmation significantly improves outcomes
Important Caveats and Monitoring
Renal Function Monitoring
While not a contraindication, acyclovir requires careful attention to renal function 5:
- Maintain adequate hydration (>2 liters daily in older children)
- Monitor renal function during therapy
- Dose reduction required in pre-existing renal impairment
- Reversible nephropathy can occur after 4 days of IV therapy in up to 20% of patients
Distinguish from Other Viral Hepatitis
The question of "viral hepatitis" requires clarification:
- For HSV hepatitis: Acyclovir is the treatment of choice
- For hepatitis B or C: Acyclovir has no role and is ineffective 6, 7, 8
- For cytomegalovirus (CMV) hepatitis: Acyclovir is not effective; ganciclovir or valganciclovir would be indicated 9
When to Suspect HSV Hepatitis in Infants
Consider HSV hepatitis when an infant presents with:
- Fever and elevated transaminases
- Mucositis or vesicular lesions (though these may be absent)
- Immunocompromised state or neonatal period
- Fulminant hepatic failure of unclear etiology
Given the safety profile of acyclovir and the high mortality of untreated HSV hepatitis, empirical acyclovir should be initiated when HSV hepatitis is suspected, even before diagnostic confirmation 4, 10.
Clinical Algorithm
- Suspect HSV hepatitis in any infant with unexplained hepatitis, especially with fever, elevated transaminases, or mucositis
- Initiate empirical acyclovir immediately (20 mg/kg IV every 8 hours for neonates)
- Send HSV PCR from blood and/or liver biopsy if available
- Ensure adequate hydration and monitor renal function
- Continue treatment for 14-21 days depending on disease severity
- Do not discontinue based solely on negative initial PCR if clinical suspicion remains high